Astec Lifesciences
795.70
-6.75(-0.84%)
Market Cap₹1,561.20 Cr
PE Ratio-
IndustryChemicals
Company Performance:
1D-0.84%
1M-6.77%
6M+10.54%
1Y-31.31%
5Y-27.11%
View Company Insightsright
More news about Astec Lifesciences
30Jun 25
Astec LifeSciences Announces ₹249.35 Crore Rights Issue at ₹890 Per Share
Astec Lifesciences, an agrochemical company, has announced a rights issue to raise ₹249.35 crores. The issue price is set at ₹890 per share for 28,01,673 shares, with an issue ratio of 1:7. The record date is July 4, 2025, and the issue will be open from July 14 to July 28, 2025. This move aims to strengthen the company's financial position and potentially fund growth initiatives.
24Jun 25
Astec Lifesciences Surges 7.5% on ₹250 Crore Rights Issue Approval
Astec Lifesciences' Board of Directors approved a rights issue to raise up to ₹250 crore through fully paid-up equity shares with a face value of ₹10 each. The stock price surged 7.5% to ₹821.50 following the announcement. Key details such as the record date and entitlement ratio are yet to be determined. The rights issue aims to strengthen the company's financial position and potentially fund growth initiatives.
19Jun 25
Astec Lifesciences to Discuss Fundraising Proposal in Upcoming Board Meeting
Astec Lifesciences, an agrochemical sector company, has announced a Board of Directors meeting on June 24 to discuss a fundraising proposal. The specific details of the potential fundraising, including its nature and amount, have not been disclosed. This meeting could have significant implications for the company's financial structure and future growth strategies.
24Apr 25
Astec Lifesciences Reports Widened Losses in Q4 FY2025 Amid Revenue Decline
Astec Lifesciences reported a consolidated net loss of ₹161.00 crore for Q4 FY2025, compared to a ₹9.70 crore loss in Q4 FY2024. Revenue declined 22.3% to ₹1,195.27 crore. Full-year FY2025 results show revenue at ₹3,813.03 crore and net loss at ₹1,347.12 crore. The Enterprise Business saw volume growth but profitability challenges, while CDMO experienced significant volume drops. Despite current challenges, management expects gradual improvement in the coming year.
23Apr 25
Astec Lifesciences Reports Widened Losses in Q4 and FY 2024-25 Amid Revenue Decline
Astec Lifesciences, a leading agrochemical company, reported increased losses for Q4 and FY 2024-25. Q4 saw a net loss of ₹160.79 crore, up from ₹9.70 crore last year, with revenue falling 22.26% to ₹119.53 crore. For FY 2024-25, net loss grew to ₹1,347.12 crore from ₹468.91 crore, while annual revenue dropped 16.78% to ₹381.30 crore. The company's debt-to-equity ratio is 2.36. Performance was impacted by reduced sales, pricing pressures, increased finance costs, and higher depreciation expenses. Management is focusing on cost optimization, product portfolio expansion, and exploring new markets to address challenges.
Astec Lifesciences
795.70
-6.75
(-0.84%)
1 Year Returns:-31.31%
Industry Peers
UPL
674.00
(+1.90%)
PI Industries
3,617.00
(+0.92%)
Sumitomo Chemical
538.30
(-1.06%)
Bayer Crop Science
5,054.90
(+2.89%)
Sharda Cropchem
850.85
(+4.30%)
Dhanuka Agritech
1,526.60
(-0.71%)
Rallis
311.70
(+0.81%)
Bharat Rasayan
10,026.00
(+0.31%)
NACL Industries
204.54
(+0.81%)